Literature DB >> 2372569

Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy.

P Valagussa1, M Zambetti, G Bonadonna, R Zucali, G Mezzanotte, U Veronesi.   

Abstract

Since 1973 we have treated T3b-T4 (stage III) breast cancer with various forms of multidisciplinary approaches through prospective trials. The present report analyses the 10-year results of 277 patients. Primary chemotherapy consisted of adriamycin plus vincristine given for three or four cycles prior to high-energy irradiation or surgery. In 205 of 277 (74%) additional chemotherapy was planned following the local-regional modality. Primary chemotherapy yielded complete plus partial remission in 62% (CR 7%). Long-term freedom from progression and overall survival were significantly improved by the addition of chemotherapy following local-regional treatment (radiotherapy or surgery). Further chemotherapy was able to significantly affect treatment outcome when it was analyzed both singly and in the presence of other prognostic variables. Thus, in our experience, the variables significantly affecting the 10-year results were represented by duration of treatment and tumor cell burden expressed by size of primary malignancy and clinical nodal status. Locally advanced breast cancer appears a pleomorphic disease difficult to control over a long period of time because of its frequent presentation with bulky tumor and the very high risk of disseminated micrometastases. Thus, the management of this stage of disease almost invariably requires a multidisciplinary approach.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372569     DOI: 10.1007/bf01806351

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY.

Authors:  C D Haagensen; A P Stout
Journal:  Ann Surg       Date:  1943-11       Impact factor: 12.969

2.  Roentgen therapy as the sole method of treatment of cancer of the breast.

Authors:  F BACLESSE
Journal:  Am J Roentgenol Radium Ther       Date:  1949-09

Review 3.  New agents and new medical treatments for advanced breast cancer.

Authors:  I C Henderson; D F Hayes; S Come; J R Harris; G Canellos
Journal:  Semin Oncol       Date:  1987-03       Impact factor: 4.929

Review 4.  The contribution of medicine to the primary treatment of breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

5.  The treatment of locally advanced breast cancer.

Authors:  G P Canellos
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

6.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.

Authors:  S M Swain; R A Sorace; C S Bagley; D N Danforth; J Bader; M N Wesley; S M Steinberg; M E Lippman
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

7.  Primary radiation therapy for locally advanced breast cancer.

Authors:  T Sheldon; D F Hayes; B Cady; L Parker; R Osteen; B Silver; A Recht; S Come; I C Henderson; J R Harris
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

8.  Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy.

Authors:  R Zucali; C Uslenghi; R Kenda; G Bonadonna
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

9.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.

Authors:  M De Lena; R Zucali; G Viganotti; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  10 in total

1.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Dose-intensified treatment of breast cancer: current results.

Authors:  C von Schilling; F Herrmann
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

3.  Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.

Authors:  Konstantinos Papadimitriou; Konstantinos Papademetriou; Alexandros Ardavanis; Panteleimon Kountourakis
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

4.  Pre-operative systemic therapy in locally advanced breast cancer: a single institution experience.

Authors:  Em Ibrahim; Am Al-Gahmi; Jm Zekri; Ss Awadalla; Tr Elkhodary; Ee Fawzy; Ya Bahadur; Me Elsayed; A Zeeneldin; Rh Al-Ahmadi; Ah Linjawi
Journal:  Ecancermedicalscience       Date:  2009-10-12

5.  Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Authors:  E Brain; C Garrino; J L Misset; I G Carbonero; M Itzhaki; E Cvitkovic; E Goldschmidt; F Burki; C Regensberg; E Pappo; R Hagipantelli; M Musset
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  The management of locally advanced breast cancer.

Authors:  R D Rubens
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

7.  A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study.

Authors:  Shekhar Sharma; K R Hiran; K Pavithran; D K Vijaykumar
Journal:  World J Surg Oncol       Date:  2009-03-30       Impact factor: 2.754

8.  Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

Authors:  E van der Wall; E J Rutgers; M J Holtkamp; J W Baars; J H Schornagel; J L Peterse; J H Beijnen; S Rodenhuis
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

9.  Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.

Authors:  A A Ezzat; E M Ibrahim; D S Ajarim; M M Rahal; M A Raja; A M Tulbah; O A Al-Malik; M Al-Shabanah; R Sorbris
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

10.  Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

Authors:  B Brenner; N Siris; E Rakowsky; E Fenig; A Sulkes; H Lurie
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.